[Pharmacokinetics of ofloxacin in patients with severe renal impairment]. 1987

H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015242 Ofloxacin A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION. DL-8280,DR-3355,Hoe-280,ORF-28489,Ofloxacin Hydrochloride,Ofloxacine,Ru-43280,Tarivid,DL 8280,DL8280,DR 3355,DR3355,Hoe 280,Hoe280,ORF 28489,ORF28489,Ru 43280,Ru43280

Related Publications

H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
January 1991, International journal of clinical pharmacology research,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
April 1988, Clinical pharmacology and therapeutics,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
February 2014, International journal of clinical pharmacology and therapeutics,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
November 1990, The Journal of antimicrobial chemotherapy,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
February 1987, Antimicrobial agents and chemotherapy,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
June 1987, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
September 1988, The Journal of antimicrobial chemotherapy,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
January 2015, Pharmacology,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
September 2017, Clinical pharmacology in drug development,
H Bandai, and Y Tsubakihara, and E Yamato, and K Yokoyama, and N Okada, and I Nakanishi, and N Iida
November 2001, Anesthesia and analgesia,
Copied contents to your clipboard!